Clinical Trials

58 enrolled 27 charts

Breast Neoplasms

NCT03013504 2024-11-06

TROIKA

503 enrolled

Breast Neoplasms

NCT03839823 2024-10-09

RIGHT Choice

222 enrolled 17 charts

Breast Neoplasms

NCT04187898 2024-09-19

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Phase 1 Completed

59 enrolled

Breast Neoplasms, Neutropenia

NCT03425656 2024-06-28

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

108 enrolled 7 charts

Breast Neoplasms

NCT03493854 2024-06-26

FeDeriCa

500 enrolled 28 charts 2 FDA

Breast Neoplasms

NCT03084237 2024-05-17

Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer

652 enrolled 15 charts

Breast Neoplasms

NCT03887130 2024-04-30

Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer

152 enrolled 14 charts

Breast Neoplasms

NCT05629949 2024-04-23

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

474 enrolled

Breast Neoplasms

NCT00003782 2024-03-21

Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes

5,351 enrolled 8 charts

Breast Neoplasms

NCT01120184 2024-03-04

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

1,095 enrolled 46 charts

Breast Neoplasms

NCT00712881 2024-02-23

Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer

126 enrolled 16 charts

Breast Neoplasms

NCT00630032 2024-02-21

TavIx

762 enrolled 14 charts

Breast Neoplasms

NCT02834403 2023-12-15

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

37 enrolled 20 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04367090 2023-09-18

Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer

Phase 1 Completed

97 enrolled

Breast Neoplasms

NCT00066443 2023-08-04

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

93 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00258375 2023-08-04

OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

15 enrolled

BreastGenitourinaryGynecologicThoracic

Breast Neoplasms

NCT00471432 2023-08-04

OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors

Phase 1 Completed

40 enrolled

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Breast Neoplasms, Male

NCT00003519 2023-06-15

Combination Chemotherapy in Treating Women With Breast Cancer

2,778 enrolled

Breast Neoplasms

NCT00004125 2023-06-15

Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes

Breast Neoplasms

NCT02586025 2023-05-22

PEONY

329 enrolled 33 charts

Breast Neoplasms

NCT02915744 2023-04-14

ATTAIN

178 enrolled 37 charts

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

NCT00121992 2023-04-04

Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

1,060 enrolled 20 charts

Breast Neoplasms

NCT00841828 2023-03-31

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

102 enrolled 10 charts

Breast Neoplasms

NCT00129896 2023-03-06

Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients

73 enrolled

Breast Neoplasms

NCT01446016 2023-01-23

CAT

38 enrolled 11 charts

Breast Neoplasms

NCT00773695 2023-01-09

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

150 enrolled

Breast Neoplasms

NCT02549677 2022-10-27

ELEGANT

Phase 4 Completed

294 enrolled

Breast Neoplasms

NCT02419742 2022-10-12

Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen

Phase 4 Completed

110 enrolled 10 charts

Breast Neoplasms

NCT03705429 2022-08-19

A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer

51 enrolled

Breast Neoplasms

NCT00248703 2022-04-22

Secondary Adjuvant Treatment for Patients With Isolated Tumor Cells in Bone Marrow

1,128 enrolled

Breast Neoplasms

NCT00887536 2022-04-20

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

1,613 enrolled

Adenocarcinoma, Breast Diseases, Breast Neoplasms, Carcinoma

NCT02643420 2022-03-02

ADVANCE

406 enrolled 19 charts

Breast Neoplasms, Neutropenia

NCT02953340 2022-03-02

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

237 enrolled 18 charts

Breast Neoplasms, Neutropenia

NCT02896855 2021-12-16

PUFFIN

243 enrolled 23 charts

Breast Neoplasms

NCT00703326 2021-12-06

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

1,144 enrolled 19 charts